Status:
UNKNOWN
Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level
Lead Sponsor:
Sheba Medical Center
Conditions:
Observational
Eligibility:
All Genders
18+ years
Brief Summary
Purpose of this study is to determine whether keeping SAA on normal or near normal level will delay progression of renal failure in patients with amyloidosis secondary to FMF.
Detailed Description
FMF is an inherited inflammatory disorder typically presented in most causes as recurrent episodes of fever and serositis. Phenotype II, another kind of this disorder, has atypical courses, when the i...
Eligibility Criteria
Inclusion
- FMF patients with amyloidosis AA
- 18 year and older
Exclusion
- patients with AA amyloidosis not related to FMF
- evidence of other primary renal disease or renovascular pathology
- evidence of renal disease secondary to any systemic illness
- presence of inflammatory, autoimmune conditions or chronic infection that could lead to high SAA level
- pregnancy
- inability to provide legal consent
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2017
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01168570
Start Date
September 1 2010
End Date
September 1 2017
Last Update
August 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Tel Litwinsky, Israel, 52621